Company Filing History:
Years Active: 2007
Title: Nick Sampas: Innovator in Cancer Classification
Introduction
Nick Sampas is an accomplished inventor based in San Jose, CA. He has made significant contributions to the field of cancer research, particularly in the classification of malignant melanoma. His innovative work focuses on the overexpression of certain marker genes, which has implications for diagnosing and treating aggressive forms of this disease.
Latest Patents
Nick Sampas holds a patent related to the classification of cancers. His patent emphasizes the role of the overexpression of marker genes, including Wnt5a, in identifying more aggressive forms of malignant melanoma. This discovery may enhance the diagnosis, profiling, and treatment of patients suffering from this condition. Furthermore, the patent suggests that inhibitors of Wnt5a activity could be beneficial in treating aggressive melanoma, with potential methods including anti-sense therapy, gene therapy, and pharmaceutical intervention. He has 1 patent to his name.
Career Highlights
Nick Sampas is currently employed at Agilent Technologies, Inc., where he continues to advance his research in cancer classification. His work has the potential to significantly impact the medical field by improving patient outcomes through better diagnostic and treatment options.
Collaborations
Some of his notable coworkers include Zohar H Yakhini and Michael L Bittner, who contribute to the collaborative efforts in cancer research at Agilent Technologies.
Conclusion
Nick Sampas is a key figure in the innovation of cancer classification, with a focus on malignant melanoma. His contributions through patents and research are paving the way for advancements in cancer diagnosis and treatment.